Fulgent Genetics, Inc. (NASDAQ:FLGT)
| Market Cap | $673.89M-19.6% |
| Revenue (ttm) | $330.27M+4.7% |
| Net Income | -$90.93M-111.5% |
| EPS | -$3.09-123.9% |
| Shares Out | 27.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 322,967 |
| Open | $24.73 |
| Previous Close | $24.78 |
| Day's Range | $23.92 - $24.73 |
| 52-Week Range | $13.46 - $31.04 |
| Beta | 1.00 |
| Analysts | Buy |
| Price Target | $19.00(-21.23%) |
| Earnings Date | Feb 26, 2027 |
About FLGT
Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating FLGT in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 26, 2027Earnings report
$FLGT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in FLGT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by FLGT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
FLGT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
FLGT Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New FLGT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to FLGT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in FLGT
| IWMiShares Russell 2000 ETF | $11.53M |
| VTIVanguard Morningstar Total Stock Market ETF | $8.52M |
| DFASDimensional - US Small Cap ETF | $4.89M |
| IWNiShares Russell 2000 Value ETF | $4.14M |
| VXFVanguard Extended Market ETF | $4.04M |
| FNDASchwab Fundamental U.S. Small Company Index ETF | $3.49M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from FLGT’s recent data — informational, not investment advice
What’s Behind the Score
News check: Mixed coverage with technical analysis showing weakness, but company included in positive market growth reports; no major analyst actions or earnings catalysts present.
Recent Insider Activity
Insider Score Trend Over Time
-50.0 since Aug 29Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| GERM | ETFMG Treatments, Testing and Advancements ETF | 1.68% |
| MYLD | Cambria ETF Trust - Cambria Micro and SmallCap Shareholder Yield ETF | 1.13% |
| NIFE | Direxion Fallen Knives ETF | 0.92% |
| XHS | State Street SPDR S&P Health Care Services ETF | 0.85% |
| GNMX | Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF | 0.66% |
| EDOC | Global X Telemedicine & Digital Health ETF | 0.47% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.44% |
| GNOM | Global X - Genomics & Biotechnology ETF | 0.39% |
| FVI | First Trust Total US Market AlphaDEX ETF | 0.38% |
| APXH | Two Roads Shared Trust - APEX HealthCare ETF | 0.23% |
| DMRS | DeltaShares S&P 600 Managed Risk ETF | 0.19% |
| PQSG | PGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF | 0.18% |
Weight is the stock’s share of each fund’s holdings.
